Management of Endometrial Cancer in 2008 Marcus E. Randall, MD, FACR Chair and Professor Markey Foundation Endowed Chair Department of Radiation Medicine.

Slides:



Advertisements
Similar presentations
Pulmonary Stereotactic Ablative Radiotherapy:
Advertisements

Oncologic Drugs Advisory Committee
“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Endometrial Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Role of Chemotherapy For Endometrial Carcinoma
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
©American Society of Clinical Oncology All rights reserved. Reprinted.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Adjuvant gemcitabine plus docetaxel for completely resected stage I-IV high grade uterine leiomyosarcoma: results of a phase II trial Martee L. Hensley,
Study proposal After 4 A Phase III intergroup trial on adjuvant therapy in radically operated endometrial cancer patients (FIGO stage IC-IIIC) with high.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Howard M. Sandler, MD University of Michigan Medical School
New Aspects of Adjuvant Therapy in Endometrial Cancer: Current Standards and Future Directions Jalid Sehouli, Dominique Koensgen, Gulten Oskay-Ozcelik,
Dpt. Obstetrics & Gynecology Catholic University - Rome
Are there benefits from chemotherapy to early endometrial cancer
Systemic Therapy for Uterine Cancer Helen J. Mackay Princess Margaret Hospital, University of Toronto.
ACRIN Abdominal Committee ACRIN Gynecologic Committee ACRIN 6671 GOG 0233 UPDATE ACRIN PI: M. ATRI GOG PI: M. GOLD.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
Involved Field Radiotherapy versus No Further Treatment in Patients with Clinical Stages IA/IIA Hodgkin Lymphoma and a “Negative” PET Scan After 3 Cycles.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Gynecologic Malignancies Dr. David Edelmann Sharett Institute of Oncology Hadassah Medical Organization.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics.
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Endometrial Cancer Commitee Minutes Chicago June 3, 2010 David Miller, Ketta Lorusso.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.
Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.
Optimal Approaches for Patients With Recurrent or Metastatic Cervical Cancer This program is supported by an educational grant from AstraZeneca.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.
PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Management of early stage cervical cancer
Adjuvant chemotherapy for early stage epithelial ovarian cancer
CCO Independent Conference Highlights
ADJUVANT THERAPY IN EARLY ENDOMETRIAL CANCER
Primaire behandeling van het endometrium carcinoma: Rol van lymfadenectomie, radiotherapie en chemotherapie Ignace Vergote PUS Gent 16/11/2006.
Comparative Results of Vaginal Relapses and Toxicity of Three 192-Ir HDR brachytherapy (BT) Schedules in Postoperative Endometrial Carcinoma (EC). Rovirosa.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Adjuvant Radiation is Required for Gastric Cancer
ACT II: The Second UK Phase III Anal Cancer Trial
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
Adjuvant Therapy in Gastric Cancer: Radiation Therapy Adds Nothing!
Joan L. Walker, M.D. Stephenson Cancer Center University of Oklahoma
Presentation transcript:

Management of Endometrial Cancer in 2008 Marcus E. Randall, MD, FACR Chair and Professor Markey Foundation Endowed Chair Department of Radiation Medicine University of Kentucky Medical Center

Endometrial Carcinoma Classification of Disease Categories – Locoregional disease Low-risk disease: stage IA grades 1-2 Intermediate-risk disease: all other stage I, stage II High-risk disease: stage III and IVA – Disseminated disease: stage IVB or recurrent

EARLY STAGE ENDOMETRIAL CANCER: INTERMEDIATE RISK DOES EVERYONE NEED RT?

GOG # 99 Complete surgical staging including pelvic and para-aortic node sampling Surgical stage IB, IC, IIA (occult) and IIB (occult) (Low and Intermediate Risk) All histologic types except serous papillary and clear cell Randomized to pelvic RT vs. no further therapy

GOG # evaluable patients 58.5% IB, 32.1% IC, only 9.4% stage II(occult) 82.3% inner and middle third invasion, only 17.6% outer third invasion 81.6% grade 1 and 2, only 18.4% grade 3

GOG # 99 Recurrence Pattern Surgery Surgery+EBRT Vagina, by randomization 13/172 (7.6%) 2/179 (1.1%) Vagina, by treatment 15/172 (8.7%) 1/179 (0.6%) received Total pelvic failure, by 20/172 (12%) 3/179 (1.7%) randomization Total pelvic failure, by 22/172 (13%) 1/179 (0.6%) treatment received

GOG # 99 Surgery Surgery +EBRT Alive (4 years) 86% 92% Dead of disease 15/202 (7.4%) 8/190 (4.2%) Intercurrent deaths 18/202 (8.9%) 14/190 (7.4%) Conclusion: The use of adjuvant RT, in women with intermediate risk endometrial cancer, decreases the risk of recurrences but has an inappreciable effect on overall survival

PROBLEMS WITH GOG # 99 The number of events was smaller than expected and approximately 50% of deaths were due to intercurrent disease. Therefore, the study was insufficiently powered to demonstrate a statistically significant survival difference. The patient population was largely composed of low risk patients.

GOG # 99 Recognized during study that patient population being accrued was mostly low risk. Therefore, “low intermediate” and “high intermediate” risk groups were defined based on GOG #33 data base.

“HIGH INTERMEDIATE RISK” Moderately-poorly differentiated tumor and Presence of LVSI and Outer 1/3 myometrial invasion Age >50 with any 2 risk factors above Age >70 with any 1 risk factor Others considered “low intermediate risk.”

GOG #99: CONCLUSION Adjunctive RT in early stage intermediate risk endometrial carcinoma decreases the risk of recurrence, but should be limited to patients whose risk factors fit a “high intermediate” risk definition. Keys et al. Gynecol Oncol 2004; 92:

Trial design for ASTEC/EN.5 Surgery High risk pathology and no macroscopic disease RANDOMIZE No external beam RTExternal beam RT Primary endpoint: Overall survival Secondary endpoint: Recurrence-free survival 905 cases 453 cases 452 cases 2% EBRT, 51% Brachytherapy 98% EBRT, 52% Brachytherapy EN.5: July ASTEC: July Analyzed by ITT principle 71% ATH BSO 29% ATH BSO PLN

HR=1.01, 95%CI= P=0.98 5y-OS: EBRT 84%, no EBRT 84% HR=0.53, 95%CI= P= y-RFS: EBRT 4%, no EBRT 7% Outcomes of ASTEC/EN.5 Overall survival Isolated vaginal or pelvic initial recurrence

JGOG2033 : Randomized phase III trial of pelvic RT versus cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma S. Sagae, N. Susumu, Y. Udagawa, K. Niwa, R. Kudo, S. Nozawa, for the Japan Gynecologic Oncology Group (ASCO 2005)

Trial design for JGOG 2033 Surgery >1/2 myometrial invasion, no residual tumor FIGO stage IB, IC, IIA, IIB, IIIA, IIIB, IIIC RANDOMIZE Pelvic Radiation Therapy (PRT) Chemotherapy (CAP) Primary endpoint: Overall Survival Secondary endpoints: PFS, incidence of toxicity 475 cases 238 cases 237 cases Enrollment: Jan Dec 2000 Analyzed on ITT principle ATH BSO+ PLN (95.3%) PRT:45-50Gy, PAN (5.7%), Brachytherapy (3.1%) Cyclophosphamide 333 mg/m2 Doxorubicin 40 mg/m2 Cisplatin 50 mg/m2 Every 4 weeks for 3 or more courses 193 cases 192 cases (Median follow up: 60.2M)

Entry 475 Randomization Pelvic Radiation Therapy (PRT): 238 Chemotherapy (CAP): 237 Subsequently eligible = did not receive PRT (18 ineligible) 27 excluded due to non-endometrioid histology Subsequently eligible = did not receive CAP (23 ineligible) 22 excluded due to non-endometrioid histology Flow chart of patients

Treatment Comparison PRT CAP Chemo Completed Tx 98.9% 97.3% Median No. of courses 3 ( 3-7 ) Median duration of Tx 5.1 wks 11.4 wks Stopped Tx due to toxicity 1.6% 4.8%

Adverse Effects Toxicity PRT (n=193) CAP (n=192) Grade (98.4%) 181(95.3%) ( 1.6%) 9 (4.7%) (chi-square test for Grade 3-4 frequency, p=0.077) Tx-related death 0 (0%) 0 (0%)

JGOG #2033: Treatment Outcomes

A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC- 9501/EORTC 55991) On behalf of NSGO and EORTC T. Hogberg 1, P. Rosenberg 1, G. Kristensen 1, CF de Oliviera 2, R dePont Christensen 1 B Sorbe 1, C Lundgren 1, H Andersson 1, T Salmi 1, NS Reed 2. 1 Nordic Society of Gynecologic Oncology, Odense, Denmark, 2 Europ Org for Research and Treatment of Cancer, Brussels, Belgium. NSGOEORTC

NSGO EC-9501/EORTC Radical surgery ATH+BSO (+PLA) RT+CT RT CT+RT OR Randomization Primary endpoint Progression-free survival (PFS) Surgical stage I, II, IIIA ( positive peritoneal fluid cytology only), or IIIC (positive pelvic lymph nodes only) Patients with serous, clear cell, or anaplastic carcinomas were eligible regardless of other risk factors 44 Gy XRT ± optional brachytherapy (BT:39%) CT : intially AP Later AP, TP, TAP, TEP 196 cases 186 cases 382 cases May 1996 to January 2007 (BT:44%)

HR 0.65 (CI ) p=0.08; estimated difference in 5-yr OS 8% from 74 % to 82 % CT not completedCT completed RT (n=196)RT + CT (n=186) NSGO EC-9501/EORTC Overall survival depending on randomization Thomas Hogberg, NSGO - 18

HR 0.51 (CI ) p=0.02; estimated difference in 5-yr CSS 10 % from 78 % to 88 % CT not completedCT completed RT (n=196)RT + CT (n=186) NSGO EC-9501/EORTC Cancer-specific survival depending on randomization Thomas Hogberg, NSGO - 19

NSGO EC-9501/EORTC Conclusion Despite that 27 % of the patients randomized to RT+CT received no or only part of the prescribed CT, RT+CT was better than RT alone as adjuvant therapy for patients with early endometrial cancer at high risk for micrometastases. Thomas Hogberg, NSGO - 25 NSGO EORTC

EARLY DISEASE: CONCLUSIONS 1.Patients with low risk disease probably do not need RT. They can be observed and RT used for salvage of local recurrences (must not immediately treat locally recurrent patients with systemic therapy on the theory they are “incurable.”

CONCLUSIONS 2.Adjuvant RT (of some sort) plays an important role in improving local control and possibly survival in most other patients with high intermediate risk endometrial carcinoma. 3. The increasing reliance on up-front surgical therapy and staging, including LN assessment, has raised new questions about the use of and appropriate extent of post-operative RT.

CONCLUSIONS 4. Given early data suggesting that chemotherapy might be effective on an adjuvant basis in high risk early stage disease, the Gynecologic Oncology Group is planning to open a study evaluating chemotherapy with cuff brachytherapy in high risk stage I-II disease.

Phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high risk, early stage endometrial cancer: ELIGIBILITY CRITERIA: Surgically staged high-intermediate risk endometrial cancer defined by GOG 99 (age >/= 70 with 1 risk factor, or >/= 50 with 2 risk factors)- using risk criteria of: Grade 2-3 tumor, (+) LVSI, outer 1/3 myometrial invasion + any age with all 3 risk criteria Stage IIb endometrial cancer of any histology Stage I-IIb papillary serous or clear cell cancers Study Chairs: Scott McMeekin, Marc Randall, Carol Aghajanian

LOCALLY ADVANCED ENDOMETRIAL CANCER

Chemotherapy for Measurable Disease Endometrial Carcinoma GOG Protocol 177: ParameterDox/Tax/Cis Dox/Cis Patients Response 77 (57%) 44 (34%) Complete Response29 (22%) 9 (7%) Median PFS 8.3 mo. 5.3 mo. Median OS15.3 mo mo. Ref: Fleming et al. JCO 22: , 2004.

Whole Abdominal Radiotherapy versus Combination Doxorubicin-Cisplatin Chemotherapy In Advanced Endometrial Carcinoma: A Randomized Phase III Trial Of The Gynecologic Oncology Group Randall ME et al. Journal of Clinical Oncology 24:36-44, 2006.

GOG #122: TREATMENT ARMS Whole Abdominal Irradiation (WAI) Doxorubicin and Cisplatin (AP Chemo ) Randomization was balanced within institutions. No other stratification was used.

TREATMENT ComparisonWAI AP Chemo Completed Tx 84% 63% Stopped tx due 3% 17% to toxicity Median duration 1.3 mos. 5.1 mos. of treatment Did not receive n=12* n=3* protocol tx (#) * Not assessed for adverse effects but included in analysis of treatment outcomes.

ADVERSE TREATMENT EFFECTS Grade 3- 4 ToxicityWAI (%)AP (%) White blood count 4 62 Abs. Neutrophil <1 85 Gastrointestinal Hepatic 3 1 Cardiac 0 15 Neurologic <1 7 Tx-related deaths n=4 n=8

GOG #122: TREATMENT OUTCOMES

SUMMARY: MANAGEMENT OF STAGE III-IV ENDOMETRIAL CARCINOMA 1.Make every effort to have patient surgically staged and maximally debulked. 2.Whole abdominal RT alone is probably no longer an acceptable treatment.

MANAGEMENT OF STAGE III-IV ENDOMETRIAL CARCINOMA 3. Combination chemotherapy has a definite place in the management of these patients, Based on GOG #122, this currently represents the treatment of choice, assuming toxicity can be limited or managed. 4.Role of combined chemo-RT is unclear, but early results are promising. Might well be the best treatment.

Chemotherapy for Advanced or Measurable Disease Endometrial Carcinoma GOG Protocol 209: Advanced or Recurrent (Measurable) Disease* Regimen I**Doxorubicin 50 mg/m2 d1 Cisplatin 60 mg/m2 d1 Paclitaxel 160 mg/m2/3h d2 Regimen IIPaclitaxel 175 mg/m2/3h Carboplatin AUC 6 d1 *Each regimen given every 3 weeks **Regimen I requires G-CSF.

Proposed GOG Study (GOG 704) Chemotherapy alone (6 cycles of Carbo-Taxol) Vs RT Concurrent with weekly cisplatin followed by 4 cycles of Carbo-Tax Study Chairs: Dr. Daniela Matei (Medical Oncology) Dr. Marc Randall (Radiation Oncology) Dr. David Mutch (Gynecologic Oncology)

QUESTIONS?